IN8BIO
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous and genetically modified approaches to develop novel cell therapies... , which are designed to effectively identify and eradicate tumor cells. IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types.
IN8BIO
Industry:
Biotechnology Health Care Therapeutics
Founded:
2016-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.in8bio.com
Total Employee:
1+
Status:
Active
Total Funding:
45.73 M USD
Technology used in webpage:
SPF Google Apps For Business Google Google Cloud Google DNS Google Domains Google Cloud DNS Google Cloud South Carolina
Current Advisors List
Board_member
2018-11-01
Current Employees Featured
Trishna Goswami Chief Medical Officer @ IN8Bio
Chief Medical Officer
2021-11-01
William Ho President, CEO & Co-founder @ IN8Bio
President, CEO & Co-founder
2016-02-01
Kate Rochlin Chief Operating Officer @ IN8Bio
Chief Operating Officer
2021-12-01
Founder
Stock Details
Investors List
Bios Partners
Bios Partners investment in Series A - IN8Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-09 | IN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer |
| 2021-11-16 | IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer |
Official Site Inspections
http://www.in8bio.com Semrush global rank: 1.44 M Semrush visits lastest month: 19.31 K
- Host name: 113.47.227.35.bc.googleusercontent.com
- IP address: 35.227.47.113
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "IN8Bio"
About IN8bio | Innovative Therapies to Treat Cancer
IN8bio was founded with the mission of developing next-generation cellular therapies for treating cancer. Dr. Lawrence Lamb, one the Company’s co-founders, is a leader in the field of gamma-delta T cells. During his postdoctoral fellowship in transplant medicine, he was the first to describe homeostatic reconstitution of gamma-delta T cells in patients who receive alpha-beta T cell …See details»
The IN8bio Management Team
IN8bio seeks to change the landscape of cancer treatment and to offer patients a novel approach to treating specific cancers. Focused on leveraging their experience in business, finance, clinical and translational research to develop …See details»
IN8Bio - Crunchbase Company Profile & Funding
IN8Bio is a biotechnology company focused on delivering a novel off-the-shelf product for the treatment of cancer.See details»
IN8Bio - The Org
IN8bio, Inc. (“IN8bio”) is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers by employing allogeneic, autologous and genetically modified gamma-delta T cells.See details»
Investor Relations | IN8bio, Inc.
The Investor Relations website contains information about IN8bio, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
IN8bio, Inc. Company Profile | New York, NY - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for IN8bio, Inc. of New York, NY. Get the latest business insights from Dun & Bradstreet.See details»
IN8bio, Inc. - AnnualReports.com
IN8bio Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring …See details»
IN8BIO, INC. Company Profile | Birmingham, AL - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for IN8BIO, INC. of Birmingham, AL. Get the latest business insights from Dun & Bradstreet.See details»
IN8bio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
About IN8bio IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue.See details»
IN8bio Corporate Presentation
IN8bio’s team has deep experience in cell therapy & oncology expertise: Diverse leadership team brings decades of extensive background in oncology discovery, business insights, franchise creation, product development, regulatory affairs, and commercializationSee details»
IN8bio - VentureRadar
IN8bio was founded with the mission of developing next-generation cellular therapies for treating cancer. Dr. Lawrence Lamb, one the Company’s co-founders, is a leader in the field of gamma-delta T cells.See details»
First clinical program to have successfully genetically ... - IN8Bio
IN8bio’s Drug Resistant Immunotherapy (DRI) is the first genetically engineered gamma-delta T cell therapy to be administered to patients.See details»
IN8Bio Company Profile - Office Locations, Competitors, Revenue …
Oct 29, 2024 IN8Bio has 1 employees across 2 locations. See insights on IN8Bio including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
IN8bio Reports First Quarter 2025 Financial Results and ... - BioSpace
8 hours ago IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue.See details»
IN8bio Reports First Quarter 2025 Financial Results and Recent …
1 day ago NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial ...See details»
IN8bio Corporate Presentation
IN8bio’s team has deep experience in cell therapy & oncology expertise: Diverse leadership team brings extensive background in oncology discovery, business insights, franchise creation, product development, regulatory affairs, and commercialization Business development and licensing expertise across biopharmaceutical and biotechnology companies.See details»
IN8bio Reports First Quarter 2025 Financial Results and Recent …
1 day ago IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue.See details»
INAB - In8Bio, Inc. Latest Stock News & Market Updates
Overview In8Bio, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative gamma-delta T cell immunotherapies for cancer treatment. Utilizing state-of-the-art approaches such as allogeneic, autologous, and genetically modified T cells, the company is at the forefront of applying …See details»
Events & Presentations - IN8bio, Inc.
Aug 12, 2024 The Investor Relations website contains information about IN8bio, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
IN8bio Reports First Quarter 2025 Financial Results and Recent …
12 hours ago William Ho, Chief Executive Officer and co-founder of IN8bio, Co-Chaired Day 2 of the Immuno-Oncology 360° (IO360°) Conference on March 25, 2025, delivering opening remarks, leading the “State ...See details»